이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Autus 밸브 조기 타당성 조사

2026년 10월 15일 업데이트: Edwards Lifesciences

외과적 폐 판막 교체를 위한 Autus 크기 조절 판막 조기 타당성 조사

Prospective, single-arm, multi-center study to evaluate safety and effectiveness of the Autus Size-Adjustable Valve in pediatric patients aged 18 months to 16 years requiring surgical pulmonary valve replacement. The Autus Valve may be expanded pre-implant to match the subject's body size. Subjects will be evaluated prior to the Autus Valve implant procedure, immediately post-implant, at hospital discharge, 30 days, 6 months, and annually through 10 years.

The Autus Valve may be expanded post-implant via transcatheter balloon dilation to accommodate growth of the subject. In subjects who undergo a post-implant valve expansion, follow-up will continue for a minimum of 1 year after the post-implant valve expansion procedure.

연구 개요

상태

모집하지 않고 적극적으로

정황

개입 / 치료

연구 유형

중재적

등록 (실제)

62

단계

  • 해당 없음

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

    • California
      • Los Angeles, California, 미국, 90027
        • Children's Hospital Los Angeles
    • Colorado
      • Aurora, Colorado, 미국, 80045
        • Children's Hospital Colorado
    • Georgia
      • Atlanta, Georgia, 미국, 30322
        • Children's Healthcare of Atlanta
    • Illinois
      • Chicago, Illinois, 미국, 60611
        • Ann and Robert H. Lurie Children's Hospital of Chicago
    • Massachusetts
      • Boston, Massachusetts, 미국, 02115
        • Boston Children's Hospital
    • Michigan
      • Ann Arbor, Michigan, 미국, 48109
        • University of Michigan - Mott Children's Hospital
    • New York
      • New York, New York, 미국, 10032
        • Columbia University Irving Medical Center/New York Presbyterian Morgan Stanley Children's Hospital
    • North Carolina
      • Durham, North Carolina, 미국, 27703
        • Duke University
    • Ohio
      • Columbus, Ohio, 미국, 43205
        • Nationwide Children's Hospital
    • Pennsylvania
      • Philadelphia, Pennsylvania, 미국, 19104
        • Children's Hospital of Philadelphia
    • Utah
      • Salt Lake City, Utah, 미국, 84113
        • University of Utah - Intermountain Primary Children's Hospital
    • Washington
      • Seattle, Washington, 미국, 98105
        • Seattle Children's Hospital

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

1년 (어린이)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

Candidates must meet all of the following inclusion criteria to be considered for enrollment in this study.

  1. Age 18 months to 16 years.

  2. Male or female.

  3. Subject has a native or repaired right ventricular outflow tract.

  4. Subject has been recommended for surgical pulmonary valve replacement by treating clinical team (cardiologist and cardiac surgeon).

  5. Subject has at least one of the following echocardiographic findings:

    1. Severe pulmonary stenosis (defined as RV to PA peak instantaneous gradient ≥60 mmHg);
    2. Moderate or greater pulmonary regurgitation;
    3. Moderate or greater pulmonary stenosis plus moderate or greater pulmonary regurgitation.
  6. Subject's body size is suitable for implantation of a study device ranging from 12.7 to 22 mm (internal diameter).

  7. Subject and parent/legal representative, where appropriate, are willing to provide informed written consent.

  8. Subject and parent/legal representative, where appropriate, and treating physician agree that the subject will return for, and comply with, all required study assessments and follow-up visits.

Exclusion Criteria:

Candidates will be excluded from the study if any of the following conditions are met:

  1. Subject requires valve replacement in a non-pulmonary position.
  2. Subject has a prosthetic valve at other valve position or will need a prosthetic valve at other valve position (i.e., anticipate additional valve replacements needed within 3 years).
  3. Subject has pulmonary arterial hypertension (defined as mean PA pressure ≥25 mmHg).
  4. Subject has pulmonary atresia and major aortopulmonary collaterals.
  5. Subject has significant peripheral pulmonary artery stenosis.
  6. Subject has an active infection requiring current systemic antibiotic therapy (if temporary illness, subject may be a candidate 4 weeks after discontinuation of antibiotics).
  7. Subject has active endocarditis or a history of infective endocarditis.
  8. Subject has renal insufficiency as determined by a serum creatinine (S-Cr) level ≥2.5 mg/dL within 60 days prior to the Screening Visit, or has end-stage renal disease.
  9. Subject has leukopenia (defined as a white blood cell (WBC) count <3.5 x 103/µL)
  10. Subject has acute or chronic anemia (defined as hemoglobin (Hgb) <10.0 g/dl or 6 mmol/L).
  11. Subject has thrombocytopenia (defined as platelet count <50 x 103/µL.
  12. Subject has a known hypersensitivity to anticoagulants and antiplatelet drugs.
  13. Subject has a known autoimmune disease or receives immunosuppressant and/or immunostimulant drugs that the Investigator or Eligibility Screening Committee (ESC) believes may negatively affect study outcomes.
  14. Subject needs emergency cardiac or vascular surgery or intervention.
  15. Positive pregnancy test prior to valve implant procedure in female subjects who have had their first menses.
  16. Subject has, in the opinion of the Investigator, a life expectancy of less than 5 years.
  17. Subject or parent/legal representative refuses blood transfusions.
  18. Subject has medical, social or psychosocial factors that, in the opinion of the Investigator or ESC, could impact safety or compliance with study procedures.
  19. Subject is participating in an investigational study of a new drug, biologic or device at the time of study screening.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 해당 없음
  • 중재 모델: 단일 그룹 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Autus Valve Arm

Pulmonary Valve Replacement Surgery with the Autus Valve

Pulmonary valve replacement surgery with the Autus Valve

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Valve Implantation Primary Safety Endpoint
기간: 30 Days post-valve implantation

Composite Endpoint: Freedom from a device-related complication through 30 days post-valve implantation as adjudicated by an independent Clinical Events Committee (CEC), including:

  • Death;
  • Valve thrombosis requiring intervention;
  • Symptomatic thromboembolism.
30 Days post-valve implantation
Valve Implantation Primary Effectiveness Endpoint
기간: 6 Months post-valve implantation

Acceptable hemodynamic performance at 6 months post-valve implantation, as assessed by the Echocardiography Core Laboratory or Clinical Events Committee, defined as:

  • A mean RVOT gradient less than or equal to 40 mmHg and
  • Less than moderate pulmonary regurgitation by transthoracic echo and
  • No Autus Valve reintervention except for valve expansion to address prosthesis-patient mismatch.
6 Months post-valve implantation

기타 결과 측정

결과 측정
측정값 설명
기간
Other Safety Outcome - Composite
기간: 6 months and annually through a minimum of 10 years and up to 11 years post-valve implantation

The following other safety outcome will be evaluated at 6 months, and annually through 10 years post-valve implantation by an independent Clinical Events Committee. The composite outcome includes device-related:

  • Death;
  • Valve thrombosis requiring intervention;
  • Symptomatic thromboembolism.
6 months and annually through a minimum of 10 years and up to 11 years post-valve implantation
Other Safety Outcome - Mortality
기간: 30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation

The following measure will be evaluated by an independent Clinical Events Committee at 30 days, 6 months, and annually through 10 years post-valve implantation. Subjects that undergo valve expansion in year 10 after device implantation will be followed for an additional year.

• Mortality, including: all cause, cardiac-related, procedure-related and device-related

30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation
Other Safety Outcome - Valve Thrombosis
기간: 30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation

The following measure will be evaluated by an independent Clinical Events Committee at 30 days, 6 months, and annually through 10 years post-valve implantation. Subjects that undergo valve expansion in year 10 after device implantation will be followed for an additional year.

• Valve thrombosis

30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation
Other Safety Outcome - Thromboembolism
기간: 30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation

The following measure will be evaluated by an independent Clinical Events Committee at 30 days, 6 months, and annually through 10 years post-valve implantation. Subjects that undergo valve expansion in year 10 after device implantation will be followed for an additional year.

• Thromboembolism

30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation
Other Safety Outcome - Cardiac or Valve Intervention
기간: 30 days, 6 months, and annually through a minimum of 510 years and up to 11 years post-valve implantation

The following measure will be evaluated by an independent Clinical Events Committee at 30 days, 6 months, and annually through 10 years post-valve implantation. Subjects that undergo valve expansion in year 10 after device implantation will be followed for an additional year.

• Other cardiac or valve intervention (surgical or transcatheter)

30 days, 6 months, and annually through a minimum of 510 years and up to 11 years post-valve implantation
Other Safety Outcome - Major Hemorrhage
기간: 30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation

The following measure will be evaluated by an independent Clinical Events Committee at 30 days, 6 months, and annually through 10 years post-valve implantation. Subjects that undergo valve expansion in year 10 after device implantation will be followed for an additional year.

• Major hemorrhage

30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation
Other Safety Outcome - Endocarditis
기간: 30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation

The following measure will be evaluated by an independent Clinical Events Committee at 30 days, 6 months, and annually through 10 years post-valve implantation. Subjects that undergo valve expansion in year 10 after device implantation will be followed for an additional year.

• Endocarditis

30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation
Other Safety Outcome - Hemolysis
기간: 30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation

The following measure will be evaluated by an independent Clinical Events Committee at 30 days, 6 months, and annually through 10 years post-valve implantation. Subjects that undergo valve expansion in year 10 after device implantation will be followed for an additional year.

• Hemolysis

30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation
Other Safety Outcome - Device Explantation
기간: 30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation

The following measure will be evaluated by an independent Clinical Events Committee at 30 days, 6 months, and annually through 10 years post-valve implantation. Subjects that undergo valve expansion in year 10 after device implantation will be followed for an additional year.

• Device explantation

30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation
Other Safety Outcome - Adverse Events (AE)
기간: 30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation

The following measure will be reported at 30 days, 6 months, and annually through 10 years post-valve implantation. Subjects that undergo valve expansion in year 10 after device implantation will be followed for an additional year.

• Adverse events

30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation
Other Safety Outcome - Valve/Stent Fracture
기간: pre-discharge, 12 months, and annually through a minimum of 5 years and up to 6 years post-valve implantation. Subjects that undergo post-implant valve expansion will be evaluated pre-discharge and at 12 months post-valve expansion.

An independent Medical Reviewer will review post-implant chest x-rays to assess for valve/stent fracture. Chest x-rays will be performed at the following timepoints: post-valve implantation at hospital discharge, and annually through 5 years post-valve implantation. If a post-implant valve expansion procedure is performed, chest x-rays will be performed at hospital discharge and 12 months post-procedure.

pre-discharge, 12 months, and annually through a minimum of 5 years and up to 6 years post-valve implantation. Subjects that undergo post-implant valve expansion will be evaluated pre-discharge and at 12 months post-valve expansion.
Other Effectiveness Outcome - Valve Implant Acute Procedural Success
기간: Immediately Post-Valve Implant Procedure

To meet the definition of success, all the parameters listed below must be achieved, as assessed by Sites using direct pressure measurements and/or transesophageal echo (TEE):

  • RV to PA peak systolic pressure gradient <40 mmHg (direct pressure measurement);
  • None or trivial pulmonary regurgitation (assessed via TEE);
  • No paravalvular leak (assessed via TEE).
Immediately Post-Valve Implant Procedure
Other Effectiveness Outcome - Pulmonary Regurgitation Grade
기간: Baseline, 30 days, 6 months, and annually through 10 years post-valve implant and 30 days, 6 months, and 12 months post-valve expansion.

Pulmonary regurgitation grade categorized as none, trivial, mild, moderate, severe as evaluated by the Echo Core Laboratory.

Baseline, 30 days, 6 months, and annually through 10 years post-valve implant and 30 days, 6 months, and 12 months post-valve expansion.
Other Effectiveness Outcome - Pulmonary Stenosis Grade
기간: Baseline, 30 days, 6 months, and annually through 10 years post-valve implant and 30 days, 6 months, and 12 months post-valve expansion.

Pulmonary stenosis grade categorized as none/trivial, mild, moderate, severe, as evaluated by the Echo Core Laboratory.

Baseline, 30 days, 6 months, and annually through 10 years post-valve implant and 30 days, 6 months, and 12 months post-valve expansion.
Other Effectiveness Outcome - Right Ventricular Measures
기간: Baseline, 30 days, 6 months, and annually through 5 years post-valve implant and 30 days, 6 months, and 12 months post-valve expansion.

Right ventricular (RV) measures, including RV dimension and strain will be evaluated by the Echo Core Laboratory.

Baseline, 30 days, 6 months, and annually through 5 years post-valve implant and 30 days, 6 months, and 12 months post-valve expansion.
Other Effectiveness Outcome - Left Ventricular Measures
기간: Baseline, 30 days, 6 months, and annually through 10 years post-valve implant and 30 days, 6 months, and 12 months post-valve expansion.

Left ventricular (LV) measures, including LV ejection fraction and strain will be evaluated by the Echo Core Laboratory.

Baseline, 30 days, 6 months, and annually through 10 years post-valve implant and 30 days, 6 months, and 12 months post-valve expansion.
Other Effectiveness Outcome - Modified Ross Functional Classification
기간: Baseline, 30 days, 6 months, and annually through 10 years post-valve implant and 30 days, 6 months, and 12 months post-valve expansion.

Modified Ross Functional Class as assessed by the Site Investigators

Baseline, 30 days, 6 months, and annually through 10 years post-valve implant and 30 days, 6 months, and 12 months post-valve expansion.
Other Effectiveness Outcome - PedsQL - Cardiac Module
기간: Baseline, 6 months and annually through 10 years post-valve implantation. Subjects that undergo post-implant valve expansion will be evaluated pre-valve expansion, and at 6 and 12 months post-valve expansion.

The Pediatric Qualify of Life Inventory (PedsQL) Cardiac Module will be administered by Site Personnel.

Baseline, 6 months and annually through 10 years post-valve implantation. Subjects that undergo post-implant valve expansion will be evaluated pre-valve expansion, and at 6 and 12 months post-valve expansion.
Other Post-Implant Valve Expansion Safety Outcome - Composite
기간: 30 days after each post-implant valve expansion procedure

Composite Endpoint: Freedom from device-related complication through 30 days post-valve expansion as adjudicated by an independent CEC:

  • Death;
  • Extracorporeal membrane oxygenation (ECMO) support;
  • Unplanned intervention (surgical or transcatheter);
  • Major hemorrhage
30 days after each post-implant valve expansion procedure
Other Post-Implant Valve Expansion Effectiveness Outcome - Acute Procedural Success
기간: Immediately after each post-implant valve expansion procedure

To meet the definition of success, at least one of the parameters listed below must be achieved after each post-implant valve expansion is performed, assessed during the same catheterization procedure:

  • RV to aortic systolic pressure ratio: ≤0.5.
  • Peak-to-peak RV to PA systolic pressure gradient: ≤15 mmHg;
  • Peak-to-peak RV to PA systolic pressure gradient: ≥50% reduction (pre vs post valve expansion).
Immediately after each post-implant valve expansion procedure
Other Post-Implant Valve Expansion Effectiveness Outcome - Hemodynamic Performance
기간: 6 months after each post-implant valve expansion procedure

Clinically acceptable hemodynamic performance at 6 months post-valve expansion procedure, as assessed by the Echo Core Laboratory via TTE, defined as:

  • Less than moderate pulmonary regurgitation (PR) by Doppler echocardiography;
  • Transvalvular gradient (assessed by CW Doppler) at 6-months is lower than the pre-expansion gradient.
6 months after each post-implant valve expansion procedure

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2024년 2월 5일

기본 완료 (실제)

2026년 8월 24일

연구 완료 (추정된)

2036년 2월 5일

연구 등록 날짜

최초 제출

2021년 7월 23일

QC 기준을 충족하는 최초 제출

2021년 8월 12일

처음 게시됨 (실제)

2021년 8월 16일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 10월 20일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 10월 15일

마지막으로 확인됨

2026년 10월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • AUT-CP-001

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

예

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .